Hims & Hers Referred to the DOJ — What It Means for the GLP-1 Telehealth Industry

On February 6, 2026, HHS General Counsel Mike Stuart posted on X that his office had referred Hims & Hers Health to the Department of Justice for investigation, citing potential violations of the Federal Food, Drug, and Cosmetic Act and "applicable Title 18 provisions." The same day, the FDA announced it would take "decisive steps" to restrict non-FDA-approved compounded GLP-1 drugs — naming Hims directly in the announcement.

This wasn't a warning letter. This was a criminal referral.

What Triggered the Referral

The immediate trigger was Hims' launch of a compounded oral semaglutide pill in early February 2026. The timing was provocative: Novo Nordisk had recently received a Commissioner's National Priority Voucher for the Wegovy pill (oral semaglutide, approved December 2025), and Eli Lilly was weeks away from FDA approval of Foundayo (orforglipron, the first non-peptide oral GLP-1).

Hims pulled the compounded pill within days. But the damage was done. Novo Nordisk followed with a lawsuit alleging unlawful mass-marketing of unapproved versions of Wegovy and Ozempic. Hims stock dropped 14% after hours.

From Hims' own 10-Q filing: the company acknowledged that "any such actions could require significant resources to address and may result in reputational harm, operational disruptions, or increased costs." In March 2026, Hims announced a "strategic shift" for its U.S. weight loss offering.

Why Title 18 Matters

Previous FDA enforcement against telehealth companies stayed in the administrative lane — warning letters, misbranding allegations, corrective action requests. The DOJ referral escalated this to potential criminal liability under Title 18 of the U.S. Code. That's the federal criminal code. The distinction between "fix your marketing or face consequences" and "you may have committed a federal crime" is not subtle.

As one legal analysis put it: "If a publicly traded company with massive legal resources is facing DOJ scrutiny, smaller entities lack the shield of obscurity."

What This Means for the Broader Industry

The Hims referral set the tone for everything that followed in 2026: 30 warning letters in March, the 503B bulks list exclusion proposal in April, and an unmistakable signal that the FDA views the compounded GLP-1 telehealth model as a regulatory priority — not a side issue.

For patients, the practical question is whether your platform operates with the kind of regulatory compliance that positions it on the right side of this enforcement wave. Platforms that clearly distinguish compounded from FDA-approved products, name their pharmacy partners, and maintain LegitScript certification are structurally positioned to survive this environment. Platforms that don't are operating on borrowed time.

The Bottom Line

The Hims DOJ referral didn't end the compounded GLP-1 market. But it ended the era in which telehealth companies could mass-market compounded GLP-1s without serious regulatory consequences. The companies that survive will be the ones that were already doing things the right way.